Discussing Lung Cancer ASCO 2023 Highlights
Focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies
August 24, 2024
Conferences
ASCO
2023
Key Points
ADAURA trial update with increase OS with adjuvant Osimertinib
KEYNOTE 789 – Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant
KEYNOTE 671 – Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
